Market Cap (In INR)
290.77 Billion
Revenue (In INR)
56.64 Billion
Net Income (In INR)
7.72 Billion
Avg. Volume
360.37 Thousand
- Currency
- INR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1585.7-2220.95
- PE
- -
- EPS
- -
- Beta Value
- 0.331
- ISIN
- INE068V01023
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Srinivas Sadu
- Employee Count
- -
- Website
- https://www.glandpharma.com
- Ipo Date
- 2020-11-20
- Details
- Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.
More Stocks
-
BBLRBubblr Inc.
BBLR
-
5870
-
KSBKSB Limited
KSB
-
0QYLRambus Inc.
0QYL
-
8293
-
GOLF
-
SLNX
-
SEIT